The combination of BRAFi and MEKi has shown clinical activity in MM [15–17, 32], but also in other cancers carrying BRAF mutations, such as THCA (specifically, the anaplastic subtype) and NSCLC [33]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.